Go to deals
Healthcare

Spital Emmental has raised US$130 million

Spital Emmental has raised US$130 million.

Spital Emmental is a regional hospital in Switzerland.

Oaklins' team in Switzerland advised Spital Emmental on negotiating the terms of their private debt with banks.

Talk to the deal team

Dr. Roberto Tracia

Partner
Bern, Switzerland
Oaklins Switzerland

Related deals

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more
EuroHospital Varna has been acquired by Intermedica Group
Healthcare

EuroHospital Varna has been acquired by Intermedica Group

EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.

Learn more
Olyos Group has acquired a controlling stake in NewScience
Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Learn more